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Abstract
Background: Several studies have reported the association of the SNP rs2414096 in the CYP19
gene with hyperandrogenism, which is one of the clinical manifestations of polycystic ovary
syndrome (PCOS). These studies suggest that SNP rs2414096 may be involved in the
etiopathogenisis of PCOS. To investigate whetherthe CYP19 gene SNP rs2414096 polymorphism
is associated with the susceptibility to PCOS, we designed a case-controlled association study
including 684 individuals.
Methods: A case-controlled association study including 684 individuals (386 PCOS patients and
298 controls) was performed to assess the association of SNP rs2414096 with PCOS. Genotyping
of SNP rs2414096 was conducted by the polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method that was performed on genomic DNA isolated from blood
leucocytes. Results were analyzed in respect to clinical test results.
Results: The genotypic distributions of rs2414096 (GG, AG, AA) in the CYP19 gene (GG, AG,
AA) in women with PCOS (0.363, 0.474, 0.163, respectively) were significantly different from that
in controls (0.242, 0.500, 0.258, respectively) (P = 0.001). E2/T was different between the AA and
GG genotypes. Age at menarche (AAM) and FSH were also significantly different among the GG,
AG, and AA genotypes in women with PCOS (P = 0.0391 and 0.0118, respectively). No differences
were observed in body mass index (BMI) and other serum hormone concentrations among the
three genotypes, either in the PCOS patients or controls.
Conclusions:  Our data suggest that SNP rs2414096 in the CYP19 gene is associated with
susceptibility to PCOS.
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Background
Polycystic ovary syndrome (PCOS) is a heterogeneous dis-
ease affecting 7.4% of fertile women in China [1]. This
syndrome is characterized by chronic anovulation, clini-
cal and/or biochemical hyperandrogenism, and polycystic
ovary, commonly leading to infertility [2-5]. Recently,
many findings have enlightened us with information
regarding the genetic background of PCOS, suggesting
that genetic factors are involved in the etiology of the dis-
order [6].
Ovarian androgen overproduction is the key physio-
pathologic feature of PCOS [7]. A number of genes encod-
ing major enzymes of the androgen metabolic pathways,
such as HSD17B6, CYP19, CYP11A1, CYP17, and INSR,
have been examined and associations reported [3,8-11] ,
although support for these associations has not been
unanimous.
The CYP19 gene is located on the long arm of chromo-
some 15 at position 15q21.1 [12]. It encodes aromatase
(P450arom), a key steroidogenic enzyme that catalyzes
the final step of estrogen biosynthesis by converting testo-
sterone and androstenedione to estradiol and estrone sep-
arately [13]. It is reported that several single nucleotide
polymorphisms (SNPs) of the CYP19 gene were associ-
ated with variation in serum androgen concentrations
among women, both within and between racial/ethnic
groups. Several studies have reported the association of
the SNP rs2414096 in the CYP19 gene with hyperandro-
genism [3,14]. These studies suggest that altered regula-
tion of this enzyme may be involved in PCOS.
In view of the strong evidence implicating the importance
of CYP19 SNP rs2414096 in androgen metabolic path-
ways, we investigated the impact of such gene polymor-
phisms on susceptibility of developing PCOS, especially
characterized by clinical or biochemical hyperandrogen-
ism in Chinese subjects.
Methods
Subjects
A total of 684 individuals, including 386 PCOS patients
and 298 non-PCOS control women (some of them with
one child or more) with normal menstrual cycles (< 32
days) and without obesity, hirsutism, cystic acne, over-
much sebum, and insulin resistance, were studied. All the
participants recruited for our study were of Chinese Han
origin, a predominant Chinese ethnic population. The
study was approved by Medical School of Nanjing Univer-
sity, and informed consent was obtained from each study
participant.
PCOS diagnostic criteria and hormone measurements
Patients with PCOS were diagnosed by the 2003 Rotter-
dam Criteria [15] (The Rotterdam ESHRE/ASRM-Spon-
sored PCOS Consensus Workshop Group, 2004). The
Rotterdam Criteria requires at least two of the following
indicators for diagnosis of PCOS: clinical or biochemical
signs of hyperandrogenism, oligomenorrhea or amenor-
rhea, and presence of polycystic ovarian (PCO) morphol-
ogy on ultrasound, with the exclusion of other causes of
hyperandrogenism such as hyperprolactinemia, andro-
gen-secreting tumors, Cushing's syndrome and nonclassic
congenital adrenal hyperplasia.
We obtained the participants' age at menarche (AAM)
through inquiry and calculated the body mass index (BMI
= body weight in kilograms divided by square of height in
meters) to assess obesity. Peripheral blood was obtained
by a single venipuncture during the 3rd to the 5th day of
the menstrual cycle for those who had menstruation and
at any time for those who had amenorrhea. All peripheral
blood samples were obtained between 8 AM and 9 AM
after a 12-hour overnight fast. None of the study partici-
pants had been taking hormonal medications, e.g. contra-
ceptive pills, for the previous three months before the
hormone measurement. Blood samples were immediately
centrifuged and then serum was separated and frozen at -
80°C until assayed. Levels of total testosterone (T), folli-
cle-stimulating hormone (FSH), luteinizing hormone
(LH), and estradiol (E2) in the sera were measured by RIA
(Beijing North Institute of Biological Technology of China
and the CIS Company of France). The E2/T ratio was used
as an index of the aromatase activity. All assays had intra-
and inter-assay coefficients of variation less than 10%.
Polymorphism genotyping analysis
Genomic DNA was isolated from human leukocytes by
using Chelex®-100 as a medium (Promega, Madison, WI,
USA). Genotyping of the rs2414096 polymorphism of the
CYP19 gene was performed with the polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) method. The sequences of the primers were 5'-TCT
GGA AAC TTT TGG TTT GAG TG-3' (forward primer) and
5'-GAT TTA GCT TAA GAG CCT TTT CTT ACA-3' (reverse
primer). PCR amplification was carried out in a total vol-
ume of 25 μL containing 50 ng of genomic DNA, 6.25
pmol of each primer, 2.5 μL STR (short tandem repeat),
10×buffer (STR 10×buffer, Promega, Madison, WI, USA)
and 1.5 U of Taq DNA polymerase (Promega, Madison,
WI, USA). The PCR was performed in a PTC-100 (MJ
Research™, Incorporated) thermocycler as follows: 30
cycles consisting of 1 minute of denaturation at 94°C, 1
minute of annealing at 60°C, and 1 minute of extension
at 72°C. An initial denaturation step of 5 minutes at 94°C
and a final extension of 10 minutes at 72°C were used.
The PCR products of 189-bp were then digested withBMC Medical Genetics 2009, 10:139 http://www.biomedcentral.com/1471-2350/10/139
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HSP92 II at 37°C overnight. A single 189 bp band corre-
sponds to the wild-type G homozygote; bands of 189,
161, and 28 bp stand for the AG heterozygotes; and 161
and 28 bp for the A homozygote. The DNA fragments
were separated by electrophoresis on a 2% agarose gel,
and visualised by staining with ethidium bromide.
Statistical analysis
Fisher's Exact Test was used to compare the CYP19 gene
genotype distributions in the case-control study. The anal-
ysis was performed using the SAS system software (SAS
Institute Inc., Cary, NC 27513-2414 USA). The results of
serum hormone levels are reported as means ± SD. Clini-
cal variables such as age and BMI, and AAM were com-
pared using one-way analysis of variance (ANOVA).
Differences in serum hormone levels among different
genotypic individuals were assessed using analysis of cov-
ariance (ANCOVA) to correct for age and BMI. P < 0.05
was considered statistically significant. Hardy-Weinberg
distribution of genotypes in the PCOS and control groups
was assessed.
Results
In 684 study subjects (Table 1), the CYP19 rs2414096
genotypic distributions were 0.310 for GG, 0.485 for AG
and 0.205 for AA. Genotypic distributions (GG, AG and
AA) in women with PCOS (0.363, 0.474, 0.163, respec-
tively) were significantly different from the controls
(0.242, 0.500, 0.258, respectively) (p = 0.001) (Table 2).
All the genotypic distributions were in Hardy-Weinberg
equilibrium.
E2/T was different between the AA and GG genotypes
(Tukey-test). Age at menarche and level of FSH were also
significantly different among GG, AG, and AA genotypes
in women with PCOS (P = 0.0391 and 0.0118, respec-
tively). There were no significant differences in BMI and
levels of other serum hormones, such as total T, LH, and
E2 (Table 3), among the three genotypes of CYP19
rs2414096 both in the patients with PCOS and the con-
trols.
Discussion
There were marked differences in allele frequencies for the
SNP rs2414096 in CYP19 gene in this case-control study.
The frequency of the A allele in the PCOS patients was
lower than that in the controls. The significant difference
in allele distribution probably indicates that the SNP of
rs2414096 in CYP19 gene is associated with the aro-
matase activity in PCOS women. The enzyme aromatase,
the single gene product of CYP 19, mediates the conver-
sion of the androgens testosterone and androstenedione
to the estrogens estradiol (E2) and estrone, respectively, in
gonadal and extragonadal tissues.
CYP 19 rs2414096 is located in an intron and therefore
does not affect the protein sequence of aromatase. How-
ever, mutations in introns sometimes can be associated
with regulatory sequences. The E2/T ratio provides impor-
tant information about aromatase activity because con-
version of androgens to estrogens is mediated by CYP19,
which suggeststhat E2/T ratio may be a direct marker of
aromatase activity. Our study demonstrates that the
rs2414096 A allele may be associated with activity of the
aromatase and further affect the conversion of androgens
to estrogens. The E2/T ratio of the AA genotype in PCOS
was significantly higher than that of the other two geno-
types and this suggests that aromatase activity was aug-
mented in the AA genotype. Reduced aromatase activity
may lead to ovarian hyperandrogenism and the develop-
ment of PCOS, which can be deduced from the facts that
a higher frequency of PCOS is observed in people with
aromatase deficiency caused by rare loss-of-function
mutations [16-18] and antral follicles taken from PCOS
women exhibits no aromatase activity [19]. The aug-
mented activity of the aromatase in the AA genotype may
protect the ovary from the development of hyperandro-
genism in PCOS patients. Our results were in contrary to
that reported by C.J.Petry et.al, [3], who found that the 'A'
allele, which was more prevalent in precocious pubarche
(PP) girls is associated with increased testosterone con-
centrations in both the Barcelona PP case-control study
and the Oxford population study. The fact that our results
were different from that of Petry et al's may lie in these
points: 1) The selection criteria for the subjects is differ-
ent. Petry et al chose the girls with PP (Age at assessment
= 9.8-10.9) as participants, while our subjects were
women with PCOS (Age at assessment = 21-33). Adoles-
cent girls are subject to physical and psychological
changes dramatically, and their endocrine levels fluctuate
Table 1: The overall characteristics of PCOS patients and controls
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more to internal and external environmental factors. 2)
The frequency distribution of alleles A/G is different
between Asians and Europeans. 3) In Petry et al's experi-
ment, the SNP 50 genotypes from girls with PP were not
in Hardy-Weinberg equilibrium (P < 0.05). Their sample
size is small and it may not be representative of the overall
ensemble, thus affecting the statistical accuracy.
FSH can induce aromatase activity, which is positively cor-
related to the E2 level. Thus, a reduced E2 level can stim-
ulate the production of FSH by negative feedback. This
may account for our observation that the concentration of
FSH in the GG genotype, which demonstrated lower aro-
matase activity, was higher compared with the other two
genotypes (table 3)
In our studies we also found that the AA genotype of
rs2414096 was associated with age at menarche in PCOS
women. C.J.Petry et al [3] also found that the distribu-
tions of the aromatase SNP-50 (rs2414096) genotype
were significantly different between PP girls and controls
in Spanish subjects. Taken together, these observations
suggest that the AA genotype of the SNP of rs2414096 in
CYP19 gene could affect the function of the aromatase
and contribute to the development of PCOS in the adoles-
cent girls. This AA genotype is associated with increased
activity of aromatase and high levels of E2, resulting in
advanced puberty.
This study suggests that the SNP of rs2414096 in CYP19
gene is positively associated with PCOS. However,
whether this SNP is a direct causal factor or it is a parallel
phenomenon due to linkage disequilibrium (LD) with
other genetic mutations is not known. The exact morbific
site still needs to be investigated and located. Several other
studies show that variation in the CYP19 gene is unlikely
to be responsible for PCOS by investigating both a tetra-
nucleotide repeat (TTTA) polymorphism in intron 4 (the
different numbers of tetranucleotide TTTA repeats in
intron 4 are associated with increased risk for breast can-
cer) and the promoter of the CYP19  gene [12,20,21].
However, since only some SNPs have been described to be
associated with PCOS, we cannot predict whether the
other sites are also associated with the etiopathogenesis of
PCOS. It's necessary to assess the polypmorphisms of the
entire CYP19 using the method of Haplotype-tags before
we can obtain any conclusion.
We failed to demonstrate the differences of the T levels
among the three genotypes of rs2414096. The etiopatho-
genesis of PCOS starts in adolescence which is the key
stage of the development of PCOS. The aromatase is
closely associated with the concentrations of androgen
Table 2: The frequency distribution of CYP19 RS2414096 in women with PCOS and controls
RS2414096 Alleles N (%) P Genotypes N (%) P
AG A A A GG G
Control 303(50.8) 293(49.2) 0.001 77(0.258) 149(0.5) 72(0.242) 0.001
PCOS 309(40.0) 463(60.0) 63(0.163) 183(0.474) 140(0.363)
Table 3: Anthropometric characteristics and serum hormone concentrations in different genotypic women with PCOS and controls
PCOS CONTROL
Genetype AA AG GG P-value AA AG GG P-value
Age (years) 27.08 ± 4.02 26.64 ± 4.6 26.53 ± 3.75 0.8061 30.65 ± 4.98 31.48 ± 4.42 32.57 ± 4.14 0.292
Menarche 
(years)
13.88 ± 1.48 14.85 ± 1.66 14.33 ± 1.68 0.0391 14.22 ± 1.01 14.52 ± 1.51 14.54 ± 1.48 0.6225
BMI (kg/m2) 23.67 ± 3.16 22.79 ± 3.80 22.31 ± 3.33 0.1619 20.88 ± 2.32 21.5 ± 2.26 21.78 ± 2.52 0.3492
FSH(IU/L) 6.35 ± 2.66 6.83 ± 3.98 8.34 ± 4.23 0.0118 6.46 ± 1.95 7.43 ± 2.48 6.97 ± 1.73 0.1674
LH(IU/L) 14.72 ± 8.05 18.54 ± 21.33 20.23 ± 16.68 0.3307 4.19 ± 2.7 4.73 ± 1.76 4.52 ± 2.03 0.5572
LH/FSH 2.55 ± 1.56 2.68 ± 1.47 2.49 ± 1.05 0.6293 0.65 ± 0.37 0.67 ± 0.28 0.68 ± 0.41 0.9569
T (nMol/L) 2.68 ± 1.55 2.87 ± 1.53 3.19 ± 1.43 0.2241 0.89 ± 0.62 1.04 ± 0.58 1.16 ± 0.73 0.3131
E2 (pMol/L) 204.57 ± 
128.63
230.9 ± 145.56 221.77 ± 
127.17







E2/T (ln) 4.15 ± 0.85 4.10 ± 0.61 3.81 ± 0.72 0.0444 5.02 ± 1.24 4.95 ± 0.99 4.93 ± 0.92 0.9431
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and estrogen and it is very important for the development
of ovary during the adolescence. C.J.Petry at al. [3] found
that the aromatase (CYP 19) gene SNP_50 (rs2414096) is
associated with features of hyperandrogenism in two pop-
ulations of young women. But for adults, the concentra-
tions of androgen and estrogen may be regulated by many
other factors including environmental factors and life
styles, so it may not be closely associated with a single fac-
tor of the SNP of rs2414096 in the CYP19 gene.
In conclusion, to our knowledge, this is the first report
demonstrating that the SNP rs2414096 in the CYP19 gene
is one of the key factors responsible for the etiopathogen-
isis of PCOS, especially in adolescence. It may be associ-
ated with the activity of the aromatase. The A allele can
stimulate aromatase activity and catalyze the conversion
of testosterone and androstenedione to estradiol and
estrone. This effect is more pronounced with higher con-
centrations of androgen, which can lead to menarche at
an earlier age.
Conclusions
This study suggests that polymorphisms of rs 2414096 in
CYP19 are associated with the pathogenesis of PCOS.
Authors' contributions
JJ, JS, HJG, FL, LK carried out DNA extraction and the
molecular genetic studies. JJ, JS, HJG, ZWW, LY, YW per-
formed the statistical analysis and drafted the manuscript.
YC, XW, HS participated in sample collection. L Y partici-
pated in the design of the study and helped to carry out
the molecular genetic studies. YW conceived the study,
and participated in its design and coordination and
helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We are extremely grateful to all the women who agreed to
participate in our study. This study was supported by the
National Natural Science Foundation of China
(30672228) and the Natural Basic Research Program of
China (973 program 2010CB945103).
References
1. Wood JR, Nelson VL, Ho C: The molecular phenotype of poly-
cystic ovary syndrome (PCOS) theca cells and new candi-
date PCOS genes defined by microarray analysis.  J Biol Chem
2003, 278:26380-26390.
2. Dumesic DA, Abbott DH, Padmanabhan V: Abbott and Vasantha
Padmanabhan. Polycystic ovary syndrome and its develop-
mental origins.  Rev Endocr Metab Disord 2007, 8(2):127-41.
3. Petry CJ, Ong KK, Michelmore KF, et al.:  Association of aro-
matase (CYP 19) gene variation with features of hyperan-
drogenism in two populations of young women.  Human
Reproduction 2005, 20(7):1837-1843.
4. Wickenheisser J K, Nelson-DeGrave V L, Hendricks K L, Legro R S:
Retinoids and Retinol Differentially Regulate Steroid Biosyn-
thesis in Ovarian Theca Cells Isolated from Normal Cycling
Women and Women with Polycystic Ovary Syndrome.  J Clin
Endocrinol Metab 2005, 90:4858-4865.
5. Knochenhauer ES, Key TJ, Kahsar-Miller M: Prevalence of the
polycystic ovary syndrome in unselected black and white
women of the southeastern United States: a prospective
study.  J Clin Endocrinol Metab 1998, 83:3078-3082.
6. Gilling-Smith C, Willis DS, Beard RW: Hypersecretion of andros-
tenedione by isolated thecal cells from polycystic ovaries.  J
Clin Endocrinol Metab 1994, 79:1158-1165.
7. Diamanti-Kandarakis E, Piperi C: Genetics of polycystic ovary
syndrome: searching for the way out of the labyrinth.  Human
Reproduction Update 2005, 11(6):631-643.
8. Jones M R, Italiano L, Wilson S G: Polymorphism in HSD17B6 is
associated with key features of polycystic ovary syndrome.
Fertil Steril 2006, 86:1438-46.
9. Gaasenbeek M, Powell BL, Sovio U, Haddad L: Large-scale analysis
of the relationship between CYP11A promoter variation,
polycystic ovarian syndrome, and serum testosterone.  J Clin
Endocrinol Metab 2004, 89:2408-13.
10. Diamanti-Kandarakis E, Bartzis M, Zapanti ED: Polymorphism
T→C (34 bp) of gene CYP17 promoter in Greek patients
with polycystic ovary syndrome.  Fertil Steril 1999, 71:431-5.
11. Jin L, Zhu X-M, Luo Q: A novel SNP at exon 17 of INSR is asso-
ciated with decreased insulin sensitivity in Chinese women
with PCOS.  Molecular Human Reproduction 2006, 3:151-155.
12. Gharani N, Waterworth D M, Batty S, White D: Association of the
steroid synthesis gene CYP11a with polycystic ovary syn-
drome and hyperandrogenism.  Human Molecular Genetics 1997,
6(3):397-402.
13. Guo Y, Xiong DH, Yang TL: Polymorphisms of estrogen-biosyn-
thesis genes CYP17 and CYP19 may influence age at
menarche: a genetic association study in Caucasian females.
Human Molecular Genetics 2006, 15(16):2401-2408.
14. Sowers MR, Wilson AL, Kardia SR, Chu J, Ferrell R: Aromatase
gene (CYP19) polymorphisms and endogenous androgen
concentrations in a multiracial/multiethnic, multisite study
of women at midlife.  Am J Med 2006, 119:23-30.
15. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group (2004) Revised 2003 consensus on diag-
nostic criteria and long-term healt h risks related to poly-
cystic ovary syndrome[J].  Fertil Steril 0000, 81(1):19-25.
16. Harada N: The structural and functional characterization of
P-450.aromatase (estrogen synthetase).  Tanpakushitsu Kakusan
Koso 1992, 37(16):3051-9.
17. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER: Molecular
basis of aromatase deficiency in an adult female with sexual
infantilism and polycystic ovaries.  Proc Natl Acad Sci USA 1993,
90(24):11673-7.
18. Belgorosky A, Pepe C, Marino R, Guercio G, Saraco N, Vaiani E,
Rivarola MA: Hypothalamic-pituitary-ovarian axis during
infancy, early and late prepuberty in an aromatase-deficient
girl who is a compound heterocygote for two new point
mutations of the CYP19 gene.  J Clin Endocrinol Metab 2003,
88(11):5127-31.
19. Takayama K, Fukaya T, Sasano H, Funayama Y, Suzuki T, Takaya R,
Wada Y, Yajima A: Immunohistochemical study of steroido-
genesis and cell proliferation in polycystic ovarian syndrome.
Hum Reprod 1996, 11(7):1387-92.
20. Söderlund D, Canto P, Carranza-Lira S, Meńdez JP: No evidence of
mutations in the P450 aromatase gene in patients with poly-
cystic ovary syndrome.  Human Reproduction 2005, 20(4):965-969.
21. Siqueira Ribeiro F, da Fonte de Amorim LM, de Almeida Simão T,
Azevedo Mendonca G, de Moura Gallo CV, Rebeiro Pinto LF: CYP19
(TTTA)n polymorphism and breast cancer risk in Brazilian
women.  Toxicology Letters 2006, 164:90-95.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/139/pre
pub